An obstacle to cancer cells

December 16, 2005

The circulation of cancer cells through the blood vessels is often the cause of metastasis. These cancer cells contaminate normal cells and the pathology spreads throughout the body. Metastasis is the main risk in cancers. In order to prevent this process from occurring, a team from the Chemistry Faculty at the Donostia-San Sebastián campus of the University of the Basque Country (UPV-EHU) analysed the connections between cancer and normal cells.

Concretely, the UPV-EHU analysed the proteins that are involved in these connections. From amongst these proteins, they chose the ones that have a single active centre. If this centre is blocked, the cancer cell will not be able to adhere itself to a healthy cell and, thus, this path of spreading the disease is blocked.

The first thing to do is to analyse the structure of the proteins chosen. This task is undertaken using computers, given that the proteins are gigantic molecules. Once the structure is analysed and with the data for the active centre of the connection, the design of a new, small molecule to block this centre is initiated.

Diminutive in order to be stealthy

The new molecule must have very special characteristics, the main one being its size: so that our immunological system does not detect it, it has to be very small; if the new synthesised molecule is any bigger, our immunological system will detect and destroy it.

Also, this new diminutive molecule must adhere itself to the active centre of the protein and, in order to do this, it has to comply to a series of requirements, i.e. it must imitate the naturally-occurring molecule that connects to the active centre.

Using all these characteristics, a series of molecules - a family of new molecules - is designed and then synthesised. It has to be taken into account that these molecules have not been created previously and do not exist naturally and, consequently, it is not known if they are stable or not.

The final step is to verify that the new synthesised molecules carry out their job.

To block and to die

First of all, trials are carried out in vitro. Here the new molecules are analysed for their capacity to adhere to the protein and neutralise it. If a cancer cell is unable to unite with a healthy cell and contaminate it, it enters a programmed stage of death and self-destructs. Moreover, as a range of molecules has been designed and developed, it has to be known which give the best results and which are the most active.

The most active molecule in the in vitro trials have to demonstrate subsequently that they are also the most active in vivo, and often the results can vary. It is possible for another molecule from the same family to have better results in vivo; thus, it is vital to carry out these trials.

Once the series of trials are over, it can be decided to enhance the molecule's efficacy or, if the results are very good, the process to convert it into medication can be initiated. But this is not the task of chemists; their job now is to follow another line of research to design more new molecules to combat other protein cancer cell connections.
-end-


Elhuyar Fundazioa

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.